Corbus Pharmaceuticals Holdings Stock Forecast NASDAQ:CRBP

Price Target and Analyst Ratings

Most Recent Rating

HC Wainwright is very positive about CRBP and gave it a "Buy" rating on October 08, 2020. The price target was changed from $6.00 to $3.00.

Last 30 Days

Historical Ratings

Date	Rating	Action	Authority	Current Price	Target Price
2021-03-16	Hold	Reiterated by	Oppenheimer	$2.18
2020-10-08	Buy	Target Lowered by	HC Wainwright	$1.23	$6.00 → $3.00
2020-09-09	Buy	Target Lowered by	HC Wainwright	$2.44	$24.00 → $6.00
2020-09-08	Outperform - Market Perform	Downgraded by	Oppenheimer	$2.23
2020-09-08	Outperform - Sector Perform	Downgraded by	Royal Bank of Canada	$2.23	$22.00 → $3.00
2020-09-08	Buy - Hold	Downgraded by	Jefferies Financial Group	$2.23	$18.00 → $2.50
2020-09-08	Buy - Neutral	Downgraded by	BTIG Research	$2.23
2020-09-08	Buy - Neutral	Downgraded by	Roth Capital	$2.23	$40.00 → $3.00
2020-08-07	Buy	Reiterated by	HC Wainwright	$6.61	$24.00
2020-07-27	Buy	Target Raised by	Jefferies Financial Group	$7.18	$17.00 → $18.00
2020-07-07	Buy	Initiated by	Roth Capital	$8.03	$40.00
2020-06-29	Buy	Reiterated by	Oppenheimer	$7.91	$28.00
2020-06-19	Buy	Reiterated by	Oppenheimer	$7.68	$28.00
2020-06-16	Buy	Initiated by	BTIG Research	$7.58	$22.00
2020-06-04	Buy	Target Raised by	Nomura Instinet	$6.89	$12.00 → $32.00
2020-06-04	Buy	Target Raised by	Nomura	$6.89	$12.00 → $32.00
2020-05-13	Buy	Reiterated by	Nomura	$6.50	$12.00
2020-05-11	Buy	Reiterated by	Oppenheimer	$6.64	$28.00

CRBP Stock Trend

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled.

Given the current short-term trend, the stock is expected to fall -40.60% during the next 3 months and, with a 90% probability hold a price between $0.57 and $0.75 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

WARNING: Trend forecast is still in the development phase and should be used with caution. Some cases might produce unexpected results such as negative prices at the end of the trend.

Data

Date	Bottom	Mid	Top
2021-09-20	$0.95	$1.10	$1.26
2021-09-21	$0.93	$1.09	$1.24
2021-09-22	$0.92	$1.08	$1.23
2021-09-23	$0.91	$1.06	$1.22
2021-09-24	$0.89	$1.05	$1.20
2021-09-27	$0.88	$1.03	$1.19
2021-09-28	$0.87	$1.02	$1.17
2021-09-29	$0.85	$1.01	$1.16
2021-09-30	$0.84	$0.99	$1.15
2021-10-01	$0.82	$0.98	$1.13
2021-10-04	$0.81	$0.96	$1.12
2021-10-05	$0.80	$0.95	$1.11
2021-10-06	$0.78	$0.94	$1.09
2021-10-07	$0.77	$0.92	$1.08
2021-10-08	$0.76	$0.91	$1.06
2021-10-11	$0.74	$0.90	$1.05
2021-10-12	$0.73	$0.88	$1.04
2021-10-13	$0.71	$0.87	$1.02
2021-10-14	$0.70	$0.85	$1.01
2021-10-15	$0.69	$0.84	$0.99
2021-10-18	$0.67	$0.83	$0.98
2021-10-19	$0.66	$0.81	$0.97
2021-10-20	$0.65	$0.80	$0.95
2021-10-21	$0.63	$0.79	$0.94
2021-10-22	$0.62	$0.77	$0.93
2021-10-25	$0.60	$0.76	$0.91
2021-10-26	$0.59	$0.74	$0.90
2021-10-27	$0.58	$0.73	$0.88
2021-10-28	$0.56	$0.72	$0.87
2021-10-29	$0.55	$0.70	$0.86

About Corbus Pharmaceuticals Holdings

Corbus Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases. Its lead product candidate includes Resunab, a novel oral endocannabinoid-mimetic drug, which is in Phase 2 clinical trials for the treatment of cystic fibrosis, systemic sclerosis, and skin-predominant dermatomyositis diseases. The company is based in N... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!